| pubmed-article:8395870 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8395870 | lifeskim:mentions | umls-concept:C0012920 | lld:lifeskim |
| pubmed-article:8395870 | lifeskim:mentions | umls-concept:C1548818 | lld:lifeskim |
| pubmed-article:8395870 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:8395870 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:8395870 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:8395870 | pubmed:dateCreated | 1993-10-6 | lld:pubmed |
| pubmed-article:8395870 | pubmed:abstractText | Topoisomerase I and II (topo I and II) are enzymes which alter the topological state of DNA through DNA strand cleavage, strand passage and religation. They participate in most aspects of DNA metabolism and are therefore vital to the cell undergoing division. Only one form of topo I has been identified whereas two isoenzymes of topo II have been described: the alpha form (170 kDa protein) and beta form (180 kDa protein). Both topo II isoenzymes have distinct nuclear localisation, are regulated independently, differ in their responsiveness to inhibitors and are differentially expressed in drug resistant cell lines. | lld:pubmed |
| pubmed-article:8395870 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8395870 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395870 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8395870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395870 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8395870 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8395870 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:8395870 | pubmed:author | pubmed-author:SmythJ FJF | lld:pubmed |
| pubmed-article:8395870 | pubmed:author | pubmed-author:CummingsJJ | lld:pubmed |
| pubmed-article:8395870 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8395870 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:8395870 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8395870 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8395870 | pubmed:pagination | 533-43 | lld:pubmed |
| pubmed-article:8395870 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:meshHeading | pubmed-meshheading:8395870-... | lld:pubmed |
| pubmed-article:8395870 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8395870 | pubmed:articleTitle | DNA topoisomerase I and II as targets for rational design of new anticancer drugs. | lld:pubmed |
| pubmed-article:8395870 | pubmed:affiliation | Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, United Kingdom. | lld:pubmed |
| pubmed-article:8395870 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8395870 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395870 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395870 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395870 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395870 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395870 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395870 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395870 | lld:pubmed |
